Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan

Shots:

• Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in Japan for RA and other future indications
• Following the approval, the companies will jointly commercialize filgotinib. The agreement will extend to additional potential indications for filgotinib including UC, CD and PsA
• Filgotinib is an investigational, oral, selective JAK1 inhibitor with its pending approval for RA in Japan, currently being evaluated in P-III SELECTION, DIVERSITY, PENGUIN study for UC, CD, PsA and P-II studies for uveitis & in the small bowel and fistulizing CD respectively

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Leo Associates